Gene: ALX1

8092
CART1|FND3|HEL23
ALX homeobox 1
protein-coding
12q21.31
Ensembl:ENSG00000180318 MIM:601527 Vega:OTTHUMG00000169820 UniprotKB:Q15699
NG_023202.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.283e-1 (AD)  6.928e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4K30.613
POU5F20.612
MTRNR2L50.612
OR10A70.61
CD1B0.598
OR2J20.596
OR52J30.587
OR2H10.586
PCAT40.582
TAS2R410.58

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
E2F1-0.335
WNT10A-0.316
MYADML2-0.313
HDDC3-0.3
C15orf65-0.291
ACRV1-0.288
MCF2-0.284
ZNF575-0.283
CHCHD6-0.282
HAS1-0.28

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
D000079AcetaldehydeAcetaldehyde affects the expression of ALX1 mRNA22634333
D000082AcetaminophenAcetaminophen results in decreased expression of ALX1 mRNA26690555
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of ALX1 gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of ALX1 mRNA16483693
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ALX1 mRNA21839799
C006780bisphenol Abisphenol A affects the expression of ALX1 mRNA23557687
C006780bisphenol Abisphenol A results in increased methylation of ALX1 promoter27312807
C006780bisphenol Abisphenol A results in decreased expression of ALX1 mRNA25181051
C054133casticincasticin results in decreased expression of ALX1 mRNA28444820
D002392Catechin[Catechin co-treated with Grape Seed Proanthocyanidins] results in decreased expression of ALX1 mRNA24763279
D003300Copper[Copper co-treated with Dietary Sucrose] results in increased expression of ALX1 mRNA26033743
D003300CopperCopper deficiency results in increased expression of ALX1 mRNA26033743
D019422Dietary Sucrose[Copper co-treated with Dietary Sucrose] results in increased expression of ALX1 mRNA26033743
D019422Dietary SucroseDietary Sucrose results in increased expression of ALX1 mRNA26033743
C061365flusilazoleflusilazole results in increased expression of ALX1 mRNA28263823
C511402Grape Seed Proanthocyanidins[Catechin co-treated with Grape Seed Proanthocyanidins] results in decreased expression of ALX1 mRNA24763279
C028007nickel monoxidenickel monoxide results in decreased expression of ALX1 mRNA19167457
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of ALX1 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of ALX1 mRNA26272509
D012715Sesame OilSesame Oil results in increased expression of ALX1 mRNA29191790
C017947sodium arsenitesodium arsenite results in increased expression of ALX1 mRNA22714537
C020806tetrabromobisphenol Atetrabromobisphenol A results in increased expression of ALX1 mRNA25172293
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of ALX1 mRNA24058054
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of ALX1 mRNA11752688
D014212TretinoinTretinoin results in increased expression of ALX1 mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of ALX1 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of ALX1 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of ALX1 mRNA23179753|2438349
D001335Vehicle EmissionsVehicle Emissions affects the methylation of ALX1 gene25560391
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA"27188386
C111237vorinostatvorinostat results in increased expression of ALX1 mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000977RNA polymerase II regulatory region sequence-specific DNA binding-IDA9753625  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0001228transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding-IDA9753625  
GO:0003700DNA-binding transcription factor activity-TAS8756334  
GO:0003714transcription corepressor activity-TAS8756334  
GO:0005515protein binding-IPI16189514  
GO:0042803protein homodimerization activity-IEA-  
GO:0046982protein heterodimerization activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IDA8756334  
GO:0001502cartilage condensation-TAS8756334  
GO:0001755neural crest cell migration-IEA-  
GO:0001843neural tube closure-IEA-  
GO:0006366transcription by RNA polymerase II-TAS8756334  
GO:0007275multicellular organism development-TAS8756334  
GO:0009952anterior/posterior pattern specification-IEA-  
GO:0010718positive regulation of epithelial to mesenchymal transition-IMP23288509  
GO:0030326embryonic limb morphogenesis-IEA-  
GO:0045893positive regulation of transcription, DNA-templated-IDA9753625  
GO:0045893positive regulation of transcription, DNA-templated-IMP23288509  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA9753625  
GO:0048704embryonic skeletal system morphogenesis-IEA-  
GO:0060021roof of mouth development-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA9753625  23288509  
GO:0005654nucleoplasm-IDA-  
GO:0005667transcription factor complex-IEA-  
GO:0005794Golgi apparatus-IDA-  
GO:0016604nuclear body-IDA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23599765Abnormal methylation of seven genes and their associations with clinical characteristics in early stage non-small cell lung cancer. (2013 Apr)Zhao YOncol Lett